The latest announcement is out from Valbiotis SA ( (FR:ALVAL) ).
Valbiotis announced its monthly voting rights and share capital information in compliance with regulatory requirements. The announcement highlights the company’s adherence to shareholder notification obligations regarding threshold crossings, emphasizing its commitment to transparency and governance.
More about Valbiotis SA
Valbiotis is a French scientific research laboratory focused on developing and marketing dietary supplements aimed at preventing and combating metabolic disorders linked to cardiovascular diseases. The company uses an innovative multi-target approach with terrestrial and marine plants to produce health nutrition products. Valbiotis operates internationally through licensing agreements and handles marketing directly in France. Established in 2014, the company maintains partnerships with top academic centers and has multiple sites in France and a subsidiary in Quebec, Canada.
YTD Price Performance: -8.91%
Average Trading Volume: 1,502
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €20.2M
For detailed information about ALVAL stock, go to TipRanks’ Stock Analysis page.